E-162 (Clovis Oncology Italy/Karus Therapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameE-162 (Clovis Oncology Italy/Karus Therapeutics)
Drug Alias NameSpiruchostatin analogues4800 research programme - EOSHDAC inibitorsKAR-2261KA-001 +[6] 
ClassificationBiologics
Mechanisms of ActionHistone deacetylase 1 inhibitors
TargetsHistone deacetylase 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesClovis Oncology IncKarus Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesClovis Oncology IncKarus Therapeutics Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A